Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer

BACKGROUND: The integration of residual cancer burden (RCB) and post‐treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a stronger predictor of long‐term outcome in unselected patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT), as compared wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Miglietta, Federica, Dieci, Maria Vittoria, Tsvetkova, Vassilena, Griguolo, Gaia, Vernaci, Grazia, Menichetti, Alice, Faggioni, Giovanni, Giarratano, Tommaso, Mioranza, Eleonora, Genovesi, Elisa, Cumerlato, Enrico, Bottosso, Michele, Saibene, Tania, Michieletto, Silvia, Lo Mele, Marcello, Conte, Pierfranco, Guarneri, Valentina
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2020
Schlagworte:
Breast Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485331/
https://ncbi.nlm.nih.gov/pubmed/32618068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0201
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge